KTTA News and Press, Pasithea Therapeutics Corp. From 12/13/23

2023-12-13 10:22:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Roblox (NYSE: RBLX ) stock is on the move Wednesday as investors react to new coverage of the video game company’s shares from Wells Fargo. Wells Fargo analysts initiat...

2023-12-13 10:05:26 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Palantir Technologies (NYSE: PLTR ) stock is in the news Wednesday after the big data company renewed a contract with UniCredit . According to a press release, UniCredit...

2023-12-13 09:49:59 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the U.S. Food and Drug Administration ( FDA ) for a PMA supplement . Tha...

2023-12-13 09:03:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company’s shares experienced major volatility on Tuesday. Investors watching KTTA stock will...

2023-12-11 12:16:39 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Pasithea Therapeutics Corp (NASDAQ: KTTA), Marker Therapeutics Inc (NASDAQ: MRKR), Macy’s Inc (...

2023-12-11 11:15:05 ET More on Pasithea Therapeutics Pasithea stock jumps 12% on update for anti-tumor drug PAS-004 Financial information for Pasithea Therapeutics For further details see: Pasithea stock soars as high as 190% on preclinical data

2023-12-11 09:56:01 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Pasithea Therapeutics Corp (NASDAQ: KTTA), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Onconova Therapeutics I...

-- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors -- -- Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models -- SOUTH SAN FRANCISCO, Calif. and ...

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the “Annual Meeting”) was...

2023-11-29 09:55:21 ET More on Pasithea Therapeutics Financial information for Pasithea Therapeutics For further details see: Pasithea stock jumps 12% on update for anti-tumor drug PAS-004